- Home
- BMR vs BOLD Comparison
BMR vs BOLD Comparison
Compare BMR & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMR
- BOLD
- Stock Information
- Founded
- BMR 2009
- BOLD 2018
- Country
- BMR Israel
- BOLD United States
- Employees
- BMR N/A
- BOLD N/A
- Industry
- BMR Computer Software: Prepackaged Software
- BOLD
- Sector
- BMR Technology
- BOLD
- Exchange
- BMR Nasdaq
- BOLD Nasdaq
- Market Cap
- BMR 59.3M
- BOLD 49.5M
- IPO Year
- BMR 2023
- BOLD 2024
- Fundamental
- Price
- BMR $2.90
- BOLD $1.96
- Analyst Decision
- BMR
- BOLD Buy
- Analyst Count
- BMR 0
- BOLD 3
- Target Price
- BMR N/A
- BOLD $22.50
- AVG Volume (30 Days)
- BMR 225.7K
- BOLD 50.0K
- Earning Date
- BMR 03-26-2025
- BOLD 04-03-2025
- Dividend Yield
- BMR N/A
- BOLD N/A
- EPS Growth
- BMR N/A
- BOLD N/A
- EPS
- BMR N/A
- BOLD N/A
- Revenue
- BMR $2,955,000.00
- BOLD N/A
- Revenue This Year
- BMR $21.52
- BOLD N/A
- Revenue Next Year
- BMR N/A
- BOLD N/A
- P/E Ratio
- BMR N/A
- BOLD N/A
- Revenue Growth
- BMR 2.25
- BOLD N/A
- 52 Week Low
- BMR $2.40
- BOLD $1.95
- 52 Week High
- BMR $10.25
- BOLD $15.24
- Technical
- Relative Strength Index (RSI)
- BMR 34.17
- BOLD N/A
- Support Level
- BMR $3.17
- BOLD N/A
- Resistance Level
- BMR $3.65
- BOLD N/A
- Average True Range (ATR)
- BMR 0.23
- BOLD 0.00
- MACD
- BMR -0.06
- BOLD 0.00
- Stochastic Oscillator
- BMR 6.74
- BOLD 0.00
About BMR Beamr Imaging Ltd.
Beamr Imaging Ltd is a video technology and image science software company. It is an innovator of video encoding, transcoding, and optimization solutions that enable high quality, performance, and unmatched bitrate efficiency for video and images. The company is conducted through one operating segment, the optimization technology for video and photo compression. The company operates in Israel, the United States, and the rest of the world, it derives a majority of its revenue from the United States.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.